Thomas Lynch named chief business officer at MindWalk
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 15 2025
0mins
- New Appointment: MindWalk has appointed Thomas Lynch as chief business officer, effective October 20.
- Previous Experience: Dr. Lynch previously held the position of director of technical sales and scientific support at Aldevron.
Analyst Views on HYFT
Wall Street analysts forecast HYFT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HYFT is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.270
Low
5.00
Averages
5.00
High
5.00
Current: 2.270
Low
5.00
Averages
5.00
High
5.00
No data
About HYFT
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
